Stasiłowicz-Krzemień Anna, Szulc Piotr, Cielecka-Piontek Judyta
Department of Pharmacognosy and Biomaterials, Faculty of Pharmacy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland.
Department of Agronomy, Poznań University of Life Sciences, Dojazd 11, 60-632 Poznan, Poland.
Pharmaceutics. 2023 Sep 4;15(9):2280. doi: 10.3390/pharmaceutics15092280.
Cannabinoids: cannabidiol (CBD), cannabidiolic acid (CBDA), and cannabichromene (CBC) are lipophilic compounds with limited water solubility, resulting in challenges related to their bioavailability and therapeutic efficacy upon oral administration. To overcome these limitations, we developed co-dispersion cannabinoid delivery systems with the biopolymer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (Soluplus) and magnesium aluminometasilicate (Neusilin US2) to improve solubility and permeability. Recognizing the potential therapeutic benefits arising from the entourage effect, we decided to work with an extract instead of isolated cannabinoids. inflorescences (Henola variety) with a confirming neuroprotective activity were subjected to dynamic supercritical CO (scCO) extraction and next they were combined with carriers (1:1 mass ratio) to prepare the co-dispersion cannabinoid delivery systems (HiE). In vitro dissolution studies were conducted to evaluate the solubility of CBD, CBDA, and CBC in various media (pH 1.2, 6.8, fasted, and fed state simulated intestinal fluid). The HiE-Soluplus delivery systems consistently demonstrated the highest dissolution rate of cannabinoids. Additionally, HiE-Soluplus exhibited the highest permeability coefficients for cannabinoids in gastrointestinal tract conditions than it was during the permeability studies using model PAMPA GIT. All three cannabinoids exhibited promising blood-brain barrier (BBB) permeability (P higher than 4.0 × 10 cm/s), suggesting their potential to effectively cross into the central nervous system. The improved solubility and permeability of cannabinoids from the HiE-Soluplus delivery system hold promise for enhancement in their bioavailability.
大麻二酚(CBD)、大麻二酚酸(CBDA)和大麻色烯(CBC)是亲脂性化合物,水溶性有限,这导致口服给药时其生物利用度和治疗效果面临挑战。为克服这些限制,我们开发了与生物聚合物聚乙烯己内酰胺 - 聚乙酸乙烯酯 - 聚乙二醇(尤特奇Eudragit E 100)和硅酸铝镁(Neusilin US2)的共分散大麻素递送系统,以提高溶解度和渗透性。认识到协同效应带来的潜在治疗益处,我们决定使用提取物而非分离的大麻素。对具有确认神经保护活性的花序(Henola品种)进行动态超临界CO₂(scCO₂)萃取,然后将其与载体按质量比1:1混合,制备共分散大麻素递送系统(HiE)。进行了体外溶出度研究,以评估CBD、CBDA和CBC在各种介质(pH 1.2、6.8、空腹和进食状态模拟肠液)中的溶解度。HiE - 尤特奇Eudragit E 100递送系统始终显示出大麻素的最高溶出率。此外,HiE - 尤特奇Eudragit E 100在胃肠道条件下对大麻素的渗透系数高于使用模型PAMPA GIT进行渗透性研究时的数值。所有三种大麻素均表现出有前景的血脑屏障(BBB)渗透性(P高于4.0×10⁻⁶ cm/s),表明它们有潜力有效进入中枢神经系统。HiE - 尤特奇Eudragit E 100递送系统中大麻素溶解度和渗透性的提高有望增强其生物利用度。